Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study against Solid Tumours and Lymphoma
News Nov 05, 2007
Santaris Pharma A/S announced the initiation of an open-label, non-randomized Phase 1 study with its HIF-1 alpha antagonist (EZN-2968) licensed outside Europe in 2006 to Enzon Pharmaceuticals, Inc. USA.
The study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha anta¬gonist in a daily for 5 days schedule in approximately 30 patients with advanced solid tumors or lymphoma.
“We are very encouraged that Enzon Pharmaceuticals has initiated the second phase 1 study with EZN-2968, a novel RNA-targeted drug based on Santaris Pharmas Locked Nucleic Acid (LNA) technology,” said Keith McCullagh, CEO of Santaris Pharma A/S. “The early safety data on the ongoing cancer trial are encouraging and Enzon is now evaluating alternative dose schedules in this second human study in patients with advanced cancer.”
The investigational drug blocks the production of Hypoxia-inducible factor-1 alpha (HIF-1 alpha), a key regulator of a large number of genes important in cancer biology, including many involved in angio¬genesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells, but ele¬vated in a variety of cancers. High expression of HIF-1 alpha is strongly correlated with poor prognosis and re¬sis¬tance to the¬rapy. Therefore, drugs that inhibit HIF-1 alpha are expected to block multiple mechanisms that control cancer progression.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019